FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan

Prognosis of recurrent high-grade glioma (HGG) is poor, although bevacizumab has been documented in that context. This study aimed to determine the independent prognostic value of fluorodeoxyglucose (FDG)-PET on progression-free survival (PFS) and overall survival (OS) of recurrent HGG after combine...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Colavolpe, Cécile, Chinot, Olivier, Metellus, Philippe, Mancini, Julien, Barrie, Maryline, Bequet-Boucard, Céline, Tabouret, Emeline, Mundler, Olivier, Figarella-Branger, Dominique, Guedj, Eric
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2012
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337300/
https://ncbi.nlm.nih.gov/pubmed/22379188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos012
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares